Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TIRZEPATIDE
- Tirzepatide to Slow Biological Aging
- The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
- Tirzepatide in Idiopathic Intracranial Hypertension Trial
- Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
- Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- GLP-1R Actions on Muscle and the Skeleton
- The Long COVID Treatment Trial
- A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
- Tirzepatide Use in People With Obesity and Type 1 Diabetes
- Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
- Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
- Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
- Tirzepatide in Obesity-Driven Endometrial Cancer
- Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
- Tirzepatide in MetALD
- Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
- Tirzepatide for Alcohol Use Disorder
- Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
- A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
- A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
- Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
- Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
- Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
- Efficacy and Safety of Tirzepatide for Weight Management
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
- A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
- A Study of BGM0504 in Participants With Obesity
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- Tirzepatide in PWS, HO and GNSO
- A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Effect of Tirzepatide on Brown Adipose Tissue in Obesity
- A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
- GLP-1s to Enhance Lasting Optimal Weight
- A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
- Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
- Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
- Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
- Bariatric Surgery vs. Semaglutide vs. Tirzepatide
- TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
- Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
- Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
- Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
- A Study of a Weight Loss Intervention in People With Endometrial Cancer
- Tirzepatide for Obesity and Meth Use Disorder
- Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
- Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss
- Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
- Study of Tirzepatide for Recovery and Alcohol Use Management
- 2024 Tirzepatide-Bariatric Surgery
- Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide
- Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
- Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
- The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
- A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
- A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
- Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
- Tirzepatide Weight Loss for MRD+ Early Breast Cancer
- Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- Study That Tests AD109 in Patients Taking GLP-1 Drugs
- Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2
- Fibrosis Lessens After Metabolic Surgery
- A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- A Study of LY3841136 in Overweight and Obese Participants
- A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
- A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
- Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
- Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
- GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial
- A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
- A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
- A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
- A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
- Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
- A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
- A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
- Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
- Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
- A Study of Tirzepatide (LY3298176) to Assess Glycemic Control in Adults With Type 2 Diabetes Switching From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)
- A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
- A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1
- A Study of LY3457263 in Obese Participants
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
- Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
- Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
- A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
- The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
- A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
- A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
- A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
- A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
- Study of Tirzepatide in Healthy Participants
- A Study of Tirzepatide in Overweight and Very Overweight Participants
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
- A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
- A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
- A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using Tirzepatide
- A Study of Tirzepatide Concentrations at Different Injection Sites in Participants With Different Body Sizes
- A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
- A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
- A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants
- A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
- A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
- A Study of Tirzepatide in Participants With Impaired Liver Function
- A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
- A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
- A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
- A Study of Tirzepatide (LY3298176) in Healthy Participants
- A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
Clinical trials list
click for details